16
Views
3
CrossRef citations to date
0
Altmetric
Miscellaneous

Novel N-hydroxamic acid hydrazide inhibitors of TNF-α synthesis

Pages 1617-1621 | Published online: 25 Feb 2005
 

Abstract

Two patent applications claim novel N-hydroxamic acid hydrazide inhibitors of TNF-α synthesis, that act via inhibition of the TNF-α-converting enzyme (TACE or ADAM-17). The hydrazides are claimed to be useful in the treatment of inflammatory diseases such as rheumatoid arthritis. The claimed sulphonylhydrazide and cyclic hydrazide derivatives both display comparable in vitro potency to Roche’s clinical development lead Ro 32-7315.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.